GlassScriptPhysician profile
Keisha Bernard
NPI 1821461849
$1,944.02
in general payments reported to CMS, 2019-2025
13 companies · $523 in 2025
The $523 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.12 · 2022: $107 · 2023: $245 · 2024: $1,058 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $234.52 | 2024-2025 | Tepezza |
| Dexcom, INC. | $233.16 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Galderma Laboratories, L.P. | $229.33 | 2022-2024 | |
| Lilly USA, LLC | $212.72 | 2022-2024 | Mounjaro, Trulicity |
| Novo Nordisk INC | $198.81 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $189.63 | 2025 | Minimed 780g |
| Merz North America, INC. | $182.87 | 2023-2024 | |
| Beta Bionics, INC. | $144.73 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $128.62 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $101.19 | 2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $50.84 | 2025 | |
| Boston Scientific Corporation | $19.04 | 2025 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keisha Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.